FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	ΩF	CHANGES	IN RE	NEFICIAL	OWNERSHI	D
SIAIEMENI	UF	CHANGES	IIN DE	NEFICIAL	OWNERSHI	

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Chaturvedi Pravin R (Last) (First) (Middle) C/O JAGUAR HEALTH, INC.				2. Issuer Name and Ticker or Trading Symbol Jaguar Health, Inc. [JAGX]								eck all applic Director Officer	all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (spec		
			(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/28/2022							below)	below) Chief Scientific			Officer		
200 PINE STREET, SUITE 400 (Street) SAN FRANCISCO CA 94104				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(City)		tate)	(Zip)		Form filed by More than One Reporting Person								ilig				
		Та	ble I - Non-D	Derivati	ve Se	ecurities	s Ac	quired,	Dis	posed o	of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3)			Da	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		, Transaction Disposed Of (E Code (Instr.		ities Acquire d Of (D) (Ins	es Acquired (A) or Of (D) (Instr. 3, 4 and		s Forr illy (D) o ollowing (I) (I		n: Direct I or Indirect E nstr. 4) (7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	ion(s)			Instr. 4)
			Table II - De	erivativo .g., puts	e Sec s, cal	urities ls, warr	Acqı ants	uired, D , option	ispo s, c	osed of onverti	, or Ben ble secu	eficially ırities)	Owned				
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date if any (Month/Day/Yea	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisabl		expiration ate	Title	Amount or Number of Shares		Transacti (Instr. 4)	on(s)		
Restricted stock units ⁽¹⁾	(2)	03/28/2022 ⁽³⁾		Α		195,934		(4)		(4)	Common Stock	195,934	\$0	195,93	34	D	

Explanation of Responses:

- 1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.
- 2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 3. The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.
- 4. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

/s/ Jonathan Wolin,

Attorney-in-Fact

03/30/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.